Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer

Fatima Mohsen Mroueh, Mohamed Noureldein, Youssef H. Zeidan, Suzan Boutary, Sara Abou Merhi Irani, Stéphanie Eid, Mary Haddad, Rasha Barakat, Frederic Harb, Joseph Costantine, Rouwaida Kanj, Erik Andre Sauleau, Allal Ouhtit, Sami T. Azar, Ali H. Eid, Assaad A. Eid*

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةArticleمراجعة النظراء

21 اقتباسات (Scopus)

ملخص

Cancer was recently annexed to diabetic complications. Furthermore, recent studies suggest that cancer can increase the risk of diabetes. Consequently, diabetes and cancer share many risk factors, but the cellular and molecular pathways correlating diabetes and colon and rectal cancer (CRC) remain far from understood. In this study, we assess the effect of hyperglycemia on cancer cell aggressiveness in human colon epithelial adenocarcinoma cells in vitro and in an experimental animal model of CRC. Our results show that Nox (NADPH oxidase enzyme) 4-induced reactive oxygen species (ROS) production is deregulated in both diabetes and CRC. This is paralleled by inactivation of the AMPK and activation of the mammalian target of rapamycin (mTOR) C1 signaling pathways, resulting in 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) accumulation, induction of DNA damage, and exacerbation of cancer cell aggressiveness, thus contributing to the genomic instability and predisposition to increased tumorigenesis in the diabetic milieu. Pharmacologic activation of AMPK, inhibition of mTORC1, or blockade of Nox4 reduce ROS production, restore the homeostatic signaling of 8-oxoguanine DNA glycosylase/8-oxodG, and lessen the progression of CRC malignancy in a diabetic milieu. Taken together, our results identify the AMPK/mTORC1/Nox4 signaling axis as a molecular switch correlating diabetes and CRC. Modulating this pathway may be a strategic target of therapeutic potential aimed at reversing or slowing the progression of CRC in patients with or without diabetes.—Mroueh, F. M., Noureldein, M., Zeidan, Y. H., Boutary, S., Irani, S. A. M., Eid, S., Haddad, M., Barakat, R., Harb, F., Costantine, J., Kanj, R., Sauleau, E.-A., Ouhtit, A., Azar, S. T., Eid, A. H., Eid, A. A. Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer. FASEB J. 33, 14051-14066 (2019). www.fasebj.org.

اللغة الأصليةEnglish
الصفحات (من إلى)14051-14066
عدد الصفحات16
دوريةFASEB Journal
مستوى الصوت33
رقم الإصدار12
المعرِّفات الرقمية للأشياء
حالة النشرPublished - ديسمبر 2019
منشور خارجيًانعم

ASJC Scopus subject areas

  • ???subjectarea.asjc.1300.1305???
  • ???subjectarea.asjc.1300.1303???
  • ???subjectarea.asjc.1300.1312???
  • ???subjectarea.asjc.1300.1311???

بصمة

أدرس بدقة موضوعات البحث “Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا